HAEM5:Acute megakaryoblastic leukaemia - Revision history

Bailey.Glen at 17:06, 3 July 2025

2025-07-03T17:06:07Z

← Older revision		Revision as of 12:06, 3 July 2025
Line 36:		Line 36:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:25, 25 May 2025

2025-05-25T21:25:31Z

← Older revision		Revision as of 16:25, 25 May 2025
Line 167:		Line 167:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 242:		Line 242:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 288:		Line 288:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:01, 25 May 2025

2025-05-25T20:01:55Z

← Older revision		Revision as of 15:01, 25 May 2025
Line 51:		Line 51:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:29, 24 March 2025

2025-03-24T17:29:34Z

← Older revision		Revision as of 12:29, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute megakaryoblastic leukaemia}}		{{DISPLAYTITLE:Acute megakaryoblastic leukaemia}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 15:		Line 14:
	<br>		<br>
	Oregon Health & Science University, Portland, OR		Oregon Health & Science University, Portland, OR

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T14:01:34Z

Removed old template contents

Show changes

Bailey.Glen at 18:37, 10 February 2025

2025-02-10T18:37:04Z

Show changes

Bailey.Glen at 18:09, 10 February 2025

2025-02-10T18:09:02Z

← Older revision		Revision as of 13:09, 10 February 2025
Line 75:		Line 75:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*Common manifestations include cytopenias (often thrombocytopenia)<ref name=":0" />.		*Common manifestations include cytopenias (often thrombocytopenia)<ref name=":0" />.
	*An association between acute megakaryoblastic leukemia and mediastrinal germ cell tumors has been described<ref>{{Cite journal\|last=Nichols\|first=C. R.\|last2=Roth\|first2=B. J.\|last3=Heerema\|first3=N.\|last4=Griep\|first4=J.\|last5=Tricot\|first5=G.\|date=1990\|title=Hematologic neoplasia associated with primary mediastinal germ-cell tumors\|url=https://www.ncbi.nlm.nih.gov/pubmed/2158625\|journal=The New England Journal of Medicine\|volume=322\|issue=20\|pages=1425–1429\|doi=10.1056/NEJM199005173222004\|issn=0028-4793\|pmid=2158625}}</ref>.		*An association between acute megakaryoblastic leukemia and mediastrinal germ cell tumors has been described<ref>{{Cite journal\|last=Nichols\|first=C. R.\|last2=Roth\|first2=B. J.\|last3=Heerema\|first3=N.\|last4=Griep\|first4=J.\|last5=Tricot\|first5=G.\|date=1990\|title=Hematologic neoplasia associated with primary mediastinal germ-cell tumors\|url=https://www.ncbi.nlm.nih.gov/pubmed/2158625\|journal=The New England Journal of Medicine\|volume=322\|issue=20\|pages=1425–1429\|doi=10.1056/NEJM199005173222004\|issn=0028-4793\|pmid=2158625}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 140:		Line 143:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	None.		None.
Line 153:		Line 156:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 160:		Line 166:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	Diagnosis		Diagnosis
Line 170:		Line 176:
	*The prognosis of AMKL is usually poorer than that of other AML types, [[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion]], and [[HAEM5:Myeloid proliferations associated with Down syndrome]]<ref name=":0" /><ref>{{Cite journal\|last=Oki\|first=Yasuhiro\|last2=Kantarjian\|first2=Hagop M.\|last3=Zhou\|first3=Xian\|last4=Cortes\|first4=Jorge\|last5=Faderl\|first5=Stefan\|last6=Verstovsek\|first6=Srdan\|last7=O'Brien\|first7=Susan\|last8=Koller\|first8=Charles\|last9=Beran\|first9=Miloslav\|date=2006\|title=Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center\|url=https://www.ncbi.nlm.nih.gov/pubmed/16123215\|journal=Blood\|volume=107\|issue=3\|pages=880–884\|doi=10.1182/blood-2005-06-2450\|issn=0006-4971\|pmid=16123215}}</ref>.		*The prognosis of AMKL is usually poorer than that of other AML types, [[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion]], and [[HAEM5:Myeloid proliferations associated with Down syndrome]]<ref name=":0" /><ref>{{Cite journal\|last=Oki\|first=Yasuhiro\|last2=Kantarjian\|first2=Hagop M.\|last3=Zhou\|first3=Xian\|last4=Cortes\|first4=Jorge\|last5=Faderl\|first5=Stefan\|last6=Verstovsek\|first6=Srdan\|last7=O'Brien\|first7=Susan\|last8=Koller\|first8=Charles\|last9=Beran\|first9=Miloslav\|date=2006\|title=Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center\|url=https://www.ncbi.nlm.nih.gov/pubmed/16123215\|journal=Blood\|volume=107\|issue=3\|pages=880–884\|doi=10.1182/blood-2005-06-2450\|issn=0006-4971\|pmid=16123215}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 218:		Line 227:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	None		None
Line 231:		Line 240:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 255:		Line 267:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*No unique chromosomal abnormality is associated with AMKL.		*No unique chromosomal abnormality is associated with AMKL.
Line 261:		Line 273:
	*Isochromosome 12p is often observed in young males with mediatinal germ tumors and AMKL<ref>{{Cite journal\|last=Orazi\|first=A.\|last2=Neiman\|first2=R. S.\|last3=Ulbright\|first3=T. M.\|last4=Heerema\|first4=N. A.\|last5=John\|first5=K.\|last6=Nichols\|first6=C. R.\|date=1993\|title=Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors\|url=https://www.ncbi.nlm.nih.gov/pubmed/8389653\|journal=Cancer\|volume=71\|issue=12\|pages=3873–3881\|doi=10.1002/1097-0142(19930615)71:123.0.co;2-1\|issn=0008-543X\|pmid=8389653}}</ref>.		*Isochromosome 12p is often observed in young males with mediatinal germ tumors and AMKL<ref>{{Cite journal\|last=Orazi\|first=A.\|last2=Neiman\|first2=R. S.\|last3=Ulbright\|first3=T. M.\|last4=Heerema\|first4=N. A.\|last5=John\|first5=K.\|last6=Nichols\|first6=C. R.\|date=1993\|title=Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors\|url=https://www.ncbi.nlm.nih.gov/pubmed/8389653\|journal=Cancer\|volume=71\|issue=12\|pages=3873–3881\|doi=10.1002/1097-0142(19930615)71:123.0.co;2-1\|issn=0008-543X\|pmid=8389653}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 296:		Line 311:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	None.		None.
Line 319:		Line 334:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 344:		Line 362:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	None.		None.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:20, 6 September 2024

2024-09-06T22:20:33Z

← Older revision		Revision as of 17:20, 6 September 2024
Line 17:		Line 17:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	~~[[AML~~\|Acute ~~Myeloid Leukemia]]~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification /~~ Subtype==		!Disease
			\|-
	~~Acute Megakaryoblastic Leukemia~~		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|Myeloid proliferations and neoplasms
			\|-
			\|Family
			\|Acute myeloid leukaemia
			\|-
			\|Type
			\|Acute myeloid leukaemia, defined by differentiation
			\|-
			\|Subtype(s)
			\|Acute megakaryoblastic leukaemia
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 21:47, 6 September 2024

2024-09-06T21:47:37Z

Show changes

Bailey.Glen: Undo revision 14803 by Bailey.Glen (talk)

2024-09-06T19:46:04Z

Undo revision 14803 by Bailey.Glen (talk)

Show changes